Ind-Swift Laboratories Q1 FY27: Profit jumps 184%

Why this quarter mattered

Ind-Swift Laboratories reported a sharp improvement in profitability for the April to June 2026 quarter (Q1 FY27), alongside healthy revenue growth. The company said its board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with limited review reports from statutory auditors Rattan Kaur & Associates. Beyond the numbers, the company also announced a corporate action: the board approved the sale of surplus land in Derabassi, Punjab, for ₹17.50 crore.

The earnings update was disclosed to exchanges on August 10, 2026, the same day the board met. The results show a notable jump in operating performance, with higher EBITDA and profit before tax compared with the year-ago quarter. The announcement also included cost-line details such as raw material consumption, employee expenses, interest costs, and depreciation.

Results announcement and reporting basis

Ind-Swift Laboratories said the Q1 FY27 results were declared on August 10, 2026. The reporting basis highlighted in the disclosures includes both standalone and consolidated numbers. In a separate consolidated performance snapshot, the company also referred to “adjusted net profit” for the quarter.

On the stock market side, the disclosure cited a current market price (CMP) of ₹237.24, up 3.87%.

Consolidated performance: income and profit lift

On a consolidated basis, total income for the quarter ended June 2026 stood at ₹199.11 crore, compared with ₹167.32 crore in the quarter ended June 2025. Consolidated profit after tax (PAT) reported for June 2026 was ₹24.68 crore versus ₹8.77 crore a year earlier.

The company also disclosed that consolidated adjusted net profit rose 183.5% year-on-year and 28.9% quarter-on-quarter to ₹24.86 crore in Q1 FY27. Net sales were reported at ₹191.45 crore, up 25.3% YoY and 12.8% QoQ. Profit before tax (PBT) stood at ₹32.56 crore in Q1 FY27, up 214.3% YoY and 172.2% QoQ.

In the same consolidated quarterly dataset, EBIT for June 2026 was ₹33.27 crore, compared with ₹9.52 crore in March 2026 and ₹11.51 crore in June 2025.

Standalone performance: revenue, EBITDA, EPS

On a standalone basis, revenue from operations came in at ₹186.08 crore (₹18,608.24 lakh) for Q1 FY27, compared with ₹153.58 crore in the year-ago quarter. Total income including other income increased to ₹193.71 crore from ₹162.58 crore.

Profit before exceptional items and tax was reported at ₹32.66 crore. After exceptional items of ₹0.24 crore (₹23.58 lakh) and total tax expense of ₹7.98 crore, standalone PAT stood at ₹24.44 crore. Basic and diluted EPS for the quarter was ₹2.81 (not annualised), compared with ₹1.18 a year earlier.

The company also stated it achieved standalone EBITDA of ₹33.32 crore for the quarter, sharply higher than ₹8.44 crore in the corresponding quarter of the previous financial year.

Costs, margins, and what drove the swing

On the cost front, consolidated total expenses increased 6.3% YoY and 5.3% QoQ to ₹165.60 crore (the quarterly dataset also shows total expenses of ₹165.84 crore for June 2026). Raw material consumption rose 25.0% YoY to ₹81.76 crore. Employee expenses increased 21.6% YoY to ₹39.56 crore.

Interest costs declined 38.3% YoY to ₹0.71 crore, while depreciation and amortisation expenses increased 13.5% YoY to ₹7.58 crore. Other income declined 47.5% YoY to ₹7.65 crore, but rose 244.6% QoQ as per the disclosure.

Taken together, the quarter reflected a combination of higher sales, controlled overall expense growth versus revenue, and lower interest outgo, alongside changes in other income and depreciation.

Board clears land sale worth ₹17.50 crore

Alongside the quarterly results, Ind-Swift Laboratories said its board approved the sale of approximately 40 bighas (roughly 10 acres) of land at Village Behra, Derabassi, Punjab. The consideration is ₹17.50 crore, to be received over a period of nine months from the August 10, 2026 agreement date.

The company cited the land as unsuitable for its manufacturing plans, according to the disclosure summary.

Key numbers at a glance

Quarterly trend snapshot (consolidated dataset)

Market impact and what investors tracked

The disclosures paired profit growth with a higher revenue base in Q1 FY27, and also highlighted a reduction in interest costs to ₹0.71 crore. Investors also had a separate corporate development to factor in: the planned sale of land for ₹17.50 crore with proceeds expected over nine months.

The market update included a CMP of ₹237.24, up 3.87% as cited in the results summary. Beyond the headline PAT growth, the cost mix and other income movement were key line items, with raw material and employee expenses both rising year-on-year while other income declined YoY but increased sharply QoQ.

Conclusion

Ind-Swift Laboratories’ Q1 FY27 disclosures showed strong year-on-year improvement in consolidated and standalone profitability, supported by higher sales and lower interest costs. The board’s approval to sell surplus land in Derabassi for ₹17.50 crore added a separate balance-sheet related action alongside the earnings. The next key monitorables are the receipt schedule of the land-sale consideration over the nine-month period from August 10, 2026 and subsequent quarterly updates on revenue, expenses, and operating profit trends.